Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclo(Prolylglycyl) SCHEMBL4247464 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL30768150 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL21736594 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| Cyclo(Prolylglycyl) SCHEMBL3016264 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| Cyclo(Prolylglycyl) SCHEMBL4243772 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL1189351 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3519704 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3519708 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL17516644 | 0.93 | KDM4E (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL464685 | 0.93 | KDM4E (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381175-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | BIOMED INDUSTRIES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220000866-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | BIOMED INDUSTRIES, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11090303-B2 | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders | BIOMED INDUSTRIES, INC. | 2021-08-17 | — | — | US | disclosed |
| US-20200054629-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | BIOMED INDUSTRIES, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381175-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | PYGB, GRN, BDNF | ALDH1A1 3725/4885KDM4E 3556/4885MAPT 141/4885 |
| US-20220000866-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | PYGB, GRN, GAP43 | ALDH1A1 3649/4885KDM4E 3539/4885MAPT 144/4885 |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | ALDH1A1 1640/4885KDM4E 1900/4885MAPT 1277/4885 |
| US-20200054629-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | PYGB, BDNF, GAP43 | ALDH1A1 3696/4885KDM4E 3846/4885MAPT 310/4885 |
| US-11090303-B2 | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders | PYGB, BDNF, GAP43 | ALDH1A1 3696/4885KDM4E 3846/4885MAPT 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.